<DOC>
	<DOC>NCT00670033</DOC>
	<brief_summary>The purpose of this study was to describe the safety and IOP-lowering efficacy of Travoprost New Formulations compared to TRAVATANÂ® and to vehicle in patients with open-angle glaucoma or ocular hypertension.</brief_summary>
	<brief_title>Travoprost New Formulations in Patients With Open-Angle Glaucoma or Ocular Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Glaucoma, Open-Angle</mesh_term>
	<mesh_term>Ocular Hypertension</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Travoprost</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>Satisfy all informed consent requirements; Diagnosed with openangle glaucoma or ocular hypertension; Able to discontinue use of all IOPlowering medications for a minimum of 5 to 28 days prior to the Eligibility 1 Visit; IOP measurements in at least 1 eye as specified in protocol; Other protocolspecified inclusion criteria may apply. Females of childbearing potential if pregnant, breastfeeding, or not using highly effective birth control measures; Any form of glaucoma other than openangle glaucoma; Severe central visual field loss in either eye; Chronic, recurrent or severe inflammatory eye disease; Clinically relevant or progressive retinal disease such as retinal degeneration, diabetic retinopathy, or retinal detachment, in the opinion of the Investigator; Bestcorrected visual acuity (BCVA) worse than 0.60 logarithm of the miniminum angle of resolution (logMAR); Intraocular surgery within the past 6 months; Ocular laser surgery within the past 3 months; Any abnormality preventing reliable applanation tonometry; Severe illness or any other conditions which would make the patient, in the opinion of the Investigator, unsuitable for the study; Other protocolspecified exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>IOP</keyword>
	<keyword>Open-angle glaucoma</keyword>
	<keyword>Ocular Hypertension</keyword>
</DOC>